Authors
Loading...
Molecular docking reveals flavonoid compounds inhibit α-glucosidase and SGLT-2 in diabetes models, indicating potential uses.
Desmiaty et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: